Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Journal Articles

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Gliceida Galarza Fortuna, Karen Sweiss, Matias Sanchez, Hira Mian, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2024-208861

Published: 2024

Journal Articles

Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT

Nada Hamad, Hiroyuki Takamatsu, Luuk Gras, Linda Koster, Laurien Baaij, Anita D'Souza, Noel Estrada-Merly, Parameswaran N. Hari, Andrew J. Cowan, Wael Saber, Minako Iida, Shinichiro Okamoto, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor-Sheng Ko, KIM Wah HO, Christopher Liam, A Sim Goh, Sui Tan, Hira Mian, Ali Bazarbachi, Brig Qamar Un N Chaudhry, Rozan Alfar, Mohamed Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Arleigh McCurdy, Alaa Elhaddad, Feng Rong Wang, Meng Lv, Mickey Boon Chai Koh, John Snowden, Stefan Schonland, Donal P McLornan, Mette Heisenberg, Patrick J Hayden, Daniel Neumann, Rafael De La Camara, Raffaella Greco, Fabio Ciceri, Anna Sureda Balari, Anna Sureda Balari, Damiano Rondelli, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger W. Niederwieser, Laurent Garderet

Blood (2024) 144 (Supplement 1): 7848.

https://doi.org/10.1182/blood-2024-209898

Published: 2024

Journal Articles

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Jehad Almasri, Bashar Hasan, Zin Tarakji, Faris W. Naffa', Lynn Warner, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 6986.

https://doi.org/10.1182/blood-2024-206645

Published: 2024

Journal Articles

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Blood (2024) 144 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2024-200071

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study

Andrew J. Cowan, Luuk Gras, Hiroyuki Takamatsu, Linda Koster, Laurien Baaij, III, Nada Hamad, Anita D'Souza, Noel Estrada-Merly, Parameswaran N. Hari, Wael Saber, Minako Iida, Shinichiro Okamoto, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor-Sheng Ko, Christopher Liam, KIM Wah HO, A Sim Goh, S Keat Tan, Alaa M. Elhaddad, Ali Bazarbachi, Brig Qamar Un N Chaudhry, Rozan Alfar, Mohamed Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Hira Mian, Arleigh McCurdy, Feng-Rong Wang, Meng Lv, Daniel Neumann, Mickey Boon Chai Koh, John Snowden, Stefan Schonland, Donal P McLornan, Patrick John Hayden, Rafael De La Camara, Raffaella Greco, Fabio Ciceri, Mette D. Hazenberg, Anna Sureda Balari, Damiano Rondelli, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger W. Niederwieser, Laurent Garderet

Blood (2024) 144 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2024-205709

Published: 2024

Journal Articles

Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study

Amaris K Balitsky, Gregory R Pond, Hira Mian, Gwynivere A Davies, Ronan Foley, Graeme Andrew McCrae Fraser, Jonathan Sussman, C. Tom Kouroukis

Blood (2024) 144 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2024-200461

Published: 2024

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Alissa Visram, Rajshekhar Chakraborty, Gregory R Pond, Hsien Seow, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alejandro Garcia-Horton, Rafael Fonseca, Hira Mian

Blood (2024) 144 (Supplement 1): 5170.3.

https://doi.org/10.1182/blood-2024-200956

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2024-206912

Published: 2024

Journal Articles

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Hira Mian, Carlyn Rose Tan, Sireesha Asoori, Rakesh Popat, Nadine Abdallah, Saurabh Chhabra, Ricardo D. Parrondo, Gregory R Pond, Thomas Martin, Brian G.M. Durie, Yi Lin

Blood (2024) 144 (Supplement 1): 704.

https://doi.org/10.1182/blood-2024-200877

Published: 2024

Journal Articles

Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Imran Haider, Darryl P. Leong, Martha L Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Mohammed Aljama, Alissa Visram, Tanya M. Wildes, Hira Mian

Blood (2024) 144 (Supplement 1): 703.

https://doi.org/10.1182/blood-2024-205524

Published: 2024

Journal Articles

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Fan Wang, Heiko Babel, Vanessa Schmitt, Muhammad Erfan Uddin, Muhamed Baljevic, Peter M. Voorhees, Cesar Rodriguez, Shaji Kumar, Hira Mian, Anders Erik Svensson, Chetasi Talati, Sven Mensing, Rajeev M Menon, Benjamin Engelhardt, Akshanth R Polepally

Blood (2024) 144 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2024-206054

Published: 2024

Journal Articles

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Rami Kotb, Darrell White, Sita Bhella, Arleigh McCurdy, Irwindeep Sandhu, Hira Mian, Julie Stakiw, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece

Blood (2023) 142 (Supplement 1): 4751.

https://doi.org/10.1182/blood-2023-190168

Published: 2023

Journal Articles

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2023-180271

Published: 2023

Journal Articles

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, Engin Gul, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez-Zepeda, Kevin Song, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Martha L Louzada, Richard LeBlanc

Blood (2023) 142 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2023-181138

Published: 2023

Journal Articles

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Martha L Louzada, Donna E. Reece, Arleigh McCurdy, Rami Kotb, Ibraheem Othman, Hira Mian, Toni Lin, Michael P Chu, Darrell White, Stephen Parkin, Engin Gul, Aniba Khan, Suzanne Trudel

Blood (2023) 142 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2023-174993

Published: 2023

Journal Articles

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Blood (2023) 142 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2023-174338

Published: 2023

NARROW

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only